KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $10.1 million.

  • Rigel Pharmaceuticals' Accumulated Expenses rose 2701.92% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 2701.92%. This contributed to the annual value of $10.1 million for FY2024, which is 1686.26% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Accumulated Expenses stood at $10.1 million, which was up 2701.92% from $7.9 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Accumulated Expenses registered a high of $10.7 million during Q4 2021, and its lowest value of $5.2 million during Q1 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' median Accumulated Expenses value was $7.9 million (recorded in 2025), while the average stood at $7.8 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Accumulated Expenses plummeted by 1706.27% in 2022, and later surged by 2701.92% in 2025.
  • Rigel Pharmaceuticals' Accumulated Expenses (Quarter) stood at $10.7 million in 2021, then dropped by 17.06% to $8.9 million in 2022, then decreased by 2.14% to $8.7 million in 2023, then rose by 16.86% to $10.1 million in 2024, then decreased by 0.73% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $7.9 million for Q2 2025, and $6.0 million during Q1 2025.